{"created":"2023-05-15T15:02:48.819144+00:00","id":85146,"links":{},"metadata":{"_buckets":{"deposit":"e1914314-9e33-4cc7-9dd2-806c76f5a2ec"},"_deposit":{"created_by":1,"id":"85146","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85146"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085146","sets":["10:28"]},"author_link":["1026402","1026401"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2022-03-09","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Uterine serous carcinoma (USC) is a rare but aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. HER2 is a potential therapeutic target because 35-44% of USCs have HER2 overexpression or gene amplification. However, the efficacy of the anti-HER2 antibody, trastuzumab, is still limited. Astatine-211 (At-211), an alpha-ray emitting radionuclide, can deliver high doses to tumors while maintaining low doses to normal tissues due to its high linear energy transfer and short range. In this study, we investigated the pharmacological effects of At-211-armed trastuzumab (211At-Trastuzumab) in human USC cell lines. 211At-Trastuzumab bound to HER2-poditive USC cells in a cell number-dependent manner. These bindings were HER2-specific because an addition of non-labeled trastuzumab blocked the cell binding. 211At-Trastuzumab showed a significant cytotoxicity in HER2-poditive USC cells. 211At-Trastuzumab is a potential radiopharmaceutical for USC treatment.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第95回日本薬理学会年会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"1026401","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sumitaka, Hasegawa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1026402","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Anti-tumor effects of alpha-ray emitting antibodies for uterine serous carcinoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Anti-tumor effects of alpha-ray emitting antibodies for uterine serous carcinoma"},{"subitem_title":"子宮体部漿液性がん細胞に対するアルファ線放出抗体の抗腫瘍効果","subitem_title_language":"en"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-03-10"},"publish_date":"2022-03-10","publish_status":"0","recid":"85146","relation_version_is_last":true,"title":["Anti-tumor effects of alpha-ray emitting antibodies for uterine serous carcinoma"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:58:35.383398+00:00"}